Abstract
Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous histological group which amount 20-25% of RCC. nccRCC have limited therapeutic options due to their exclusion from phase III randomized trials. Therefore, the aim of this study was to investigate the efficacy of pembrolizumab- axitinib in chromophobe and papillary metastatic RCC patients enrolled in the I-RARE observational ongoing study (Meet-URO 23).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
